Skip to articles
All insights

Structural Heart

PASCAL enters US tricuspid repair—before the pivotal data arrive

US approval expands the tricuspid TEER conversation, while unpublished randomised outcomes keep comparative claims and South African assumptions off limits.

Editorial illustration of a catheter approaching a tricuspid valve for edge-to-edge leaflet repair.
Original, non-diagnostic illustration of the T-TEER concept. It does not depict the PASCAL device or a clinical procedure, and no endorsement is implied. Original Aperture Science editorial illustration; resized for web · Copyright Aperture Science 2026; editorial use on this site
US FDA approval announced · pivotal randomised outcomes not yet public · no comparative superiority claimRetrospective coverage · 19 Oct 2026 – 25 Oct 2026

For healthcare professionals and procurement teams. This is editorial analysis, not patient advice, a product recommendation or a statement of South African availability.

Why it matters

On 21 October, Edwards Lifesciences announced US Food and Drug Administration approval of the PASCAL Precision system for transcatheter edge-to-edge repair of the tricuspid valve. The stated indication covers improvement in quality of life and functional status in patients with symptomatic severe tricuspid regurgitation despite optimal medical therapy, who are at intermediate or greater surgical risk and considered suitable for T-TEER by a multidisciplinary heart team. [1]

That is a meaningful structural-heart milestone, but it arrives with an unusual publication sequence: the randomised CLASP II TR outcomes that will allow clinicians to examine the pivotal comparison in detail are not yet public. They are scheduled for presentation at TCT on 2 November. [4] The approval and the unanswered evidence questions therefore need to be held together.

What happened

The manufacturer’s 21 October regulatory release describes a US indication centred on symptoms, severe tricuspid regurgitation, optimal medical therapy, surgical risk and heart-team selection. [1] The wording matters because it defines a specific population; it does not establish suitability for every patient with tricuspid regurgitation.

The release states that the PASCAL system is now approved for tricuspid repair and separately reports FDA approval of PASCAL Ace with Capture Clarity for degenerative mitral TEER. These are distinct indications and should not be merged in clinical or procurement communication.

The patient-selection boundary is explicit:

“appropriate for transcatheter edge-to-edge tricuspid valve repair by a multidisciplinary heart team” — Edwards regulatory announcement. [1]

This is attributable manufacturer wording. No independent expert quotation has been added.

The data—and what is not yet available

CLASP II TR is a prospective, multicentre, open-label randomised trial comparing PASCAL T-TEER plus optimal medical therapy with optimal medical therapy alone. The published design paper describes 450 randomised participants assigned 2:1 after central screening, with severe or greater tricuspid regurgitation assessed by an independent echocardiographic core laboratory. [3]

Its primary endpoint is a six-month hierarchical composite incorporating all-cause mortality, durable right-ventricular assist device or heart transplant, tricuspid intervention, heart-failure hospitalisations and improvement in the Kansas City Cardiomyopathy Questionnaire overall summary score. Follow-up includes 30 days, three, six and 12 months, then annual assessment through five years. [2] [3]

Why the endpoint needs careful reading

A hierarchical composite does not treat every component as interchangeable. When results are released, teams will need the statistical method, component ordering, treatment effect, uncertainty intervals and the contribution of health-status change versus harder clinical events. A positive overall result would not automatically mean reductions in mortality or hospitalisation; each component must be examined.

As of this review, ClinicalTrials.gov displays the study design but no posted results, while the TCT programme lists the randomised clinical and health-status outcomes for 2 November. [2] [4] We therefore report no event rates, confidence intervals, p-values or subgroup effects. None is publicly available from these primary sources yet.

FDA describes PMA as its most stringent device marketing application and says approval depends on sufficient valid scientific evidence for the intended use. [5] That regulatory conclusion should not be recast as proof of superiority over another repair device, transcatheter replacement, surgery or medical therapy beyond the evidence actually reviewed and disclosed.

How T-TEER works

Tricuspid regurgitation occurs when the valve leaflets do not coapt adequately and blood flows backward from the right ventricle into the right atrium during systole. In T-TEER, a catheter system is advanced through the venous circulation to the right heart. An implant approximates selected leaflet segments, aiming to reduce the regurgitant opening while preserving forward flow.

The concept is straightforward; execution is not. Leaflet anatomy, coaptation gap, imaging quality, right-ventricular function, haemodynamics and concomitant disease all influence assessment. The new approval does not remove the need for anatomical screening, intraprocedural imaging expertise or multidisciplinary selection.

South African professional implications

This is a US approval. It does not demonstrate SAHPRA authorisation, South African availability, reimbursement, local pricing or inclusion in any hospital formulary. Aperture Science has no verified distribution or endorsement relationship with the featured technology, and this article makes none.

For local structural-heart programmes, the immediate value is preparatory. Teams can define the questions they will apply to the forthcoming data: Was the overall result driven mainly by quality-of-life change or by clinical events? How durable was tricuspid reduction? What were the major adverse events and reinterventions? Which anatomies were excluded? How did missing data and crossovers affect interpretation?

Procurement review should follow clinical governance rather than precede it. A future local evaluation would need current regulatory status, approved labelling, training and imaging requirements, consumables, service support, post-procedure follow-up and full episode-of-care cost. These are evaluation domains, not a recommendation to acquire or use the system.

What to watch next

The 2 November CLASP II TR presentation is the next decisive checkpoint. Priority items are the primary hierarchical analysis, component-level outcomes, safety definition, residual regurgitation, functional status, quality of life and the consistency of effect across prespecified subgroups. [4]

Publication of the full report and FDA approval package will matter because slides and a manufacturer release cannot substitute for complete methods, adverse-event tables and regulatory labelling. Until then, the correct conclusion is narrow: a new US T-TEER option has been approved for a defined population, while the public clinical evidence package remains incomplete. This article is professional commentary, not patient medical advice.

Source material

References

  1. Edwards Lifesciences. FDA Approval of Edwards Lifesciences’ PASCAL Precision System Opens New Treatment Pathway for Patients With Tricuspid Valve Disease. Published 21 October 2026; checked 26 October 2026.
  2. ClinicalTrials.gov. Edwards PASCAL Transcatheter Valve Repair System Pivotal Clinical Trial (CLASP II TR), NCT04097145. Record checked 26 October 2026.
  3. Ailawadi G, Davidson CJ, Anderson AS, et al. Design and Rationale of the CLASP II TR Randomized Trial for Severe Tricuspid Regurgitation. American Heart Journal. Published online 9 October 2026. doi:10.1016/j.ahj.2026.107627.
  4. TCT 2026 Program Guide. Transcatheter Tricuspid Valve Repair with the PASCAL System vs. Medical Therapy for Severe, Symptomatic Tricuspid Regurgitation. Scheduled 2 November 2026; checked 26 October 2026.
  5. US Food and Drug Administration. Premarket Approval (PMA): regulatory standard and evidentiary framework. Checked 26 October 2026.